CL2019003161A1 - Métodos de tratamiento selectivo del asma usando antagonistas de il-17. - Google Patents
Métodos de tratamiento selectivo del asma usando antagonistas de il-17.Info
- Publication number
- CL2019003161A1 CL2019003161A1 CL2019003161A CL2019003161A CL2019003161A1 CL 2019003161 A1 CL2019003161 A1 CL 2019003161A1 CL 2019003161 A CL2019003161 A CL 2019003161A CL 2019003161 A CL2019003161 A CL 2019003161A CL 2019003161 A1 CL2019003161 A1 CL 2019003161A1
- Authority
- CL
- Chile
- Prior art keywords
- antagonists
- selective
- treatment methods
- asthma treatment
- asthma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501806P | 2017-05-05 | 2017-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003161A1 true CL2019003161A1 (es) | 2020-02-07 |
Family
ID=62245372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003161A CL2019003161A1 (es) | 2017-05-05 | 2019-11-04 | Métodos de tratamiento selectivo del asma usando antagonistas de il-17. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10676522B2 (enExample) |
| EP (1) | EP3619536A1 (enExample) |
| JP (1) | JP2020518604A (enExample) |
| KR (1) | KR20190142398A (enExample) |
| CN (1) | CN110582702A (enExample) |
| AU (1) | AU2018263159A1 (enExample) |
| BR (1) | BR112019023141A2 (enExample) |
| CA (1) | CA3062179A1 (enExample) |
| CL (1) | CL2019003161A1 (enExample) |
| MX (1) | MX2019013160A (enExample) |
| RU (1) | RU2019139387A (enExample) |
| TW (1) | TW201842933A (enExample) |
| WO (1) | WO2018203289A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3689907A1 (en) * | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| WO2021211430A1 (en) * | 2020-04-17 | 2021-10-21 | Eli Lilly And Company | Treatment of respiratory disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0308324D0 (en) | 2003-04-10 | 2003-05-14 | Piezoptic Ltd | A chemical sensing device |
| CN1898564A (zh) * | 2003-12-24 | 2007-01-17 | 惠氏公司 | 治疗哮喘的方法 |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| CN101326195B9 (zh) | 2005-12-13 | 2022-11-11 | 伊莱利利公司 | 抗il-17抗体 |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| JP6161233B2 (ja) | 2008-03-31 | 2017-07-12 | ジェネンテック, インコーポレイテッド | 喘息の治療及び診断のための組成物及び方法 |
| KR101318549B1 (ko) | 2008-09-29 | 2013-10-16 | 로슈 글리카트 아게 | 인간 il17 에 대한 항체 및 이의 용도 |
| MX371052B (es) | 2013-02-08 | 2020-01-14 | Novartis Ag | Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios. |
| BR112016008694A2 (pt) * | 2013-10-23 | 2017-10-03 | Genentech Inc | Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit |
| WO2015191783A2 (en) * | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| US11278618B2 (en) * | 2014-09-10 | 2022-03-22 | Novartis Ag | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
| GB201508832D0 (en) | 2015-05-22 | 2015-07-01 | Novartis Ag | A method for detecting an analyte |
-
2018
- 2018-05-03 TW TW107114983A patent/TW201842933A/zh unknown
- 2018-05-03 US US15/969,952 patent/US10676522B2/en active Active
- 2018-05-04 JP JP2019560115A patent/JP2020518604A/ja active Pending
- 2018-05-04 CA CA3062179A patent/CA3062179A1/en not_active Abandoned
- 2018-05-04 RU RU2019139387A patent/RU2019139387A/ru not_active Application Discontinuation
- 2018-05-04 KR KR1020197035578A patent/KR20190142398A/ko not_active Abandoned
- 2018-05-04 CN CN201880029544.7A patent/CN110582702A/zh active Pending
- 2018-05-04 EP EP18727435.2A patent/EP3619536A1/en not_active Withdrawn
- 2018-05-04 AU AU2018263159A patent/AU2018263159A1/en not_active Abandoned
- 2018-05-04 MX MX2019013160A patent/MX2019013160A/es unknown
- 2018-05-04 BR BR112019023141-2A patent/BR112019023141A2/pt not_active Application Discontinuation
- 2018-05-04 WO PCT/IB2018/053106 patent/WO2018203289A1/en not_active Ceased
-
2019
- 2019-11-04 CL CL2019003161A patent/CL2019003161A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019013160A (es) | 2020-02-05 |
| BR112019023141A2 (pt) | 2020-07-28 |
| TW201842933A (zh) | 2018-12-16 |
| JP2020518604A (ja) | 2020-06-25 |
| US20180319881A1 (en) | 2018-11-08 |
| KR20190142398A (ko) | 2019-12-26 |
| RU2019139387A (ru) | 2021-06-07 |
| CN110582702A (zh) | 2019-12-17 |
| CA3062179A1 (en) | 2018-11-08 |
| EP3619536A1 (en) | 2020-03-11 |
| US10676522B2 (en) | 2020-06-09 |
| AU2018263159A1 (en) | 2019-11-07 |
| WO2018203289A1 (en) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011995A2 (es) | Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia | |
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| MX2017011834A (es) | Macrociclos peptidomimeticos y usos de los mismos. | |
| MX2019014009A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| MX2024000348A (es) | Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| MX2017008875A (es) | Anticuerpos biespecificos contra cd3 y cd20. | |
| CL2015002807A1 (es) | Terapia de combinación | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| MX2019008085A (es) | Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros. | |
| MX2016005159A (es) | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. | |
| MX2015010724A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| MX370664B (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| UY34654A (es) | Inhibidores de la beta-secretasa | |
| BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| EA201992707A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
| MX2021008305A (es) | Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa. | |
| MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
| AR101476A1 (es) | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) | |
| CL2020001123A1 (es) | Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren. | |
| UY35438A (es) | Procedimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| UY34991A (es) | Inhibidores de la beta-secretasa |